Factor XII Deficiency in Mexico: High Prevalence in the General Population and Patients with Venous Thromboembolic Disease

Introduction. Thrombosis is one of the leading causes of morbidity and mortality world-wide. Venous thromboembolic disease (VTD) is considered a new epidemic. FXII de-ficiency is supposed to be a cause of thrombosis. To search for unknown causes of thrombosis in our population, our aim was to determine if FXII deficiency can be considered a risk factor for VTD.Methods. Young adult Mexican patients with at least one VTD episode and healthy controls were included in this prospective, observational, controlled study. Liver and renal function tests, blood cytometry, and blood coagulation assays were performed. Plasma FXII activity and its concentration were evaluated.Results. Over a two-year period, 250 patients and 250 controls were included. FXII activity was significantly lower in the control group compared to patients with VTD ( p = 0.005). However, percentage of patients and controls with FXII deficiency was 8.8 and 9.2%, respectively ( p = 1.000). No significant association was found between FXII deficiency and VTD ( p = 1.0). FXII plasma concentration was lower in controls vs. patients with VTD: 4.05 vs. 6.19 ng/mL ( p < 0.001). Percentage of patients with low FXII plasma concentration was 1.6% and 6.0% in patients and controls, respectively ( p = 0.010).Conclusions. FXII deficiency is a frequent finding in patients with VTD and controls in Mexico. Some patients with FXII deficiency had normal APTT result, an effect not described above. FXII plasma concentration was lower in patients with low activity. (c) 2023 Instituto Mexicano del Seguro Social (IMSS). Published by Elsevier Inc. All rights reserved.